Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kalvis Hornburg"'
Autor:
Tarek H. Mouhieddine, Adam S. Sperling, Robert Redd, Jihye Park, Matthew Leventhal, Christopher J. Gibson, Salomon Manier, Amin H. Nassar, Marzia Capelletti, Daisy Huynh, Mark Bustoros, Romanos Sklavenitis-Pistofidis, Sabrin Tahri, Kalvis Hornburg, Henry Dumke, Muhieddine M. Itani, Cody J. Boehner, Chia-Jen Liu, Saud H. AlDubayan, Brendan Reardon, Eliezer M. Van Allen, Jonathan J. Keats, Chip Stewart, Shaadi Mehr, Daniel Auclair, Robert L. Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, David P. Steensma, Jacob P. Laubach, Paul G. Richardson, Jerome Ritz, Benjamin L. Ebert, Robert J. Soiffer, Lorenzo Trippa, Gad Getz, Donna S. Neuberg, Irene M. Ghobrial
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Multiple myeloma (MM) is treated with induction chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. Here, the authors show that the presence of clonal haematopoiesis of indeterminate potential
Externí odkaz:
https://doaj.org/article/26a4f18ed00849e6bce820eacad6b32d
Autor:
Choi-Fong Cho, Justin M. Wolfe, Colin M. Fadzen, David Calligaris, Kalvis Hornburg, E. Antonio Chiocca, Nathalie Y. R. Agar, Bradley L. Pentelute, Sean E. Lawler
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
In vitroblood-brain barrier (BBB) models are crucial tools for screening brain-penetrating compounds. Here the authors develop a self-assembling BBB spheroid model with superior performance to the standard transwell BBB model, and use their platform
Externí odkaz:
https://doaj.org/article/66ff86f13d85438c93395cad172f6fbe
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This file contains the legends for the supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403647a09b3635dce22c4f3b8c519b1a
https://doi.org/10.1158/1078-0432.22473741
https://doi.org/10.1158/1078-0432.22473741
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
Purpose:Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12.Patients and Methods:This phase Ib/II study aimed to determine the safety and tolerability of ulocupluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d7c946d4f8b2b3fdf89b50a1279664
https://doi.org/10.1158/1078-0432.c.6528591
https://doi.org/10.1158/1078-0432.c.6528591
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
The figures show that patients received 10 mg ulocuplumab could reach higher concentration peak and larger dose-corrected area under curve (both p < 0.001).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::153ca41d7fcc6ab8e1b99fc0d6f3904f
https://doi.org/10.1158/1078-0432.22473753.v1
https://doi.org/10.1158/1078-0432.22473753.v1
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure shows Absolute cell numbers in the peripheral blood of patients receiving 10mg/kg ulocuplumab (absolute count, cells/uL).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f08c65058363e1de82e8b0fc83392e
https://doi.org/10.1158/1078-0432.22473744
https://doi.org/10.1158/1078-0432.22473744
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure shows (A) Proportion of circulating CD34+ stem cells (% of living cells, all patients combined). (B) Proportion of circulating CD138+ myeloma cells (% of living cells, all patients combined) (C) Distribution of CD34+ stem cells in respond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d55193434afd6c9a2660c69f9aed4d
https://doi.org/10.1158/1078-0432.22473750
https://doi.org/10.1158/1078-0432.22473750
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure presents a consort diagram showing (A) the dose-escalation scheme for BMS-936564 (ulocuplumab), (B) the dose-expansion scheme, including Arms A & B, of the study and (C) Number of patients at each dose level in the phase I and II studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5a4c5a0bde393f0e59926e66f78ad8
https://doi.org/10.1158/1078-0432.22473756.v1
https://doi.org/10.1158/1078-0432.22473756.v1
Autor:
Robert A. Redd, Matthew Leventhal, Irene M. Ghobrial, Nikhil C. Munshi, Christopher J. Gibson, Jerome Ritz, Amin Nassar, Chip Stewart, Jihye Park, Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Cody J. Boehner, David P. Steensma, Saud H. AlDubayan, Daniel Auclair, Lorenzo Trippa, Muhieddine M. Itani, Benjamin L. Ebert, Kalvis Hornburg, Shaadi Mehr, Mark Bustoros, Robert L. Schlossman, Henry Dumke, Jacob P. Laubach, Adam S. Sperling, Gad Getz, Salomon Manier, Paul G. Richardson, Eliezer M. Van Allen, Tarek H. Mouhieddine, Sabrin Tahri, Kenneth C. Anderson, Robert J. Soiffer, Daisy Huynh, Donna Neuberg, Brendan Reardon, Chia Jen Liu, Jonathan J Keats
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is t
Autor:
Peter Sabbatini, Stacey Chuma, Rachid Baz, Jacob P. Laubach, Robert A. Redd, Alexandra Savell, Raymond P. Perez, Pamela S. Becker, Patrick Henrick, Kenneth C. Anderson, Oksana Zavidij, Chia Jen Liu, Kalvis Hornburg, Romanos Sklavenitis-Pistofidis, Michael Robbins, Kaitlen Reyes, Paul G. Richardson, Irene M. Ghobrial
Publikováno v:
Clinical Cancer Research. 26:344-353
Purpose: Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. Patients and Methods: This phase Ib/II study aimed to determine the safety and tolerability of ulocupl